Efineptakin alfa Clinical Trials (2026): 5 Studies for AIDS-Related Kaposi Sarcoma & Carcinoma, Non-Small-Cell Lung
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 Efineptakin alfa clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including AIDS-Related Kaposi Sarcoma & Carcinoma, Non-Small-Cell Lung) and 115 total planned enrollment. Most recent activity: NCT05465954 (Sep 2031).
Efineptakin alfa clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | completed | terminated | Total |
|---|---|---|---|---|
| P1 | 1 | 2 | 3 | |
| P2 | 1 | 1 | 2 |
Efineptakin alfa clinical trials by indication
High Grade Astrocytic Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05465954 | — | P2 | active not recruiting | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma |
AIDS-Related Kaposi Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04893018 | — | P1 | terminated | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV |
Carcinoma, Non-Small-Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04984811 | — | P2 | terminated | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC |
Refractory Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05075603 | — | P1 | completed | Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy |
Recurrent Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04588038 | — | P1 | terminated | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery |
Terminated and withdrawn Efineptakin alfa trials (3)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04588038terminatedNT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
- NCT04984811terminatedNT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
- NCT04893018terminatedNT-I7 for Kaposi Sarcoma in Patients With or Without HIV
All Efineptakin alfa trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05465954 | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | P2 | active not recruiting | 53 | Mayo Clinic | Jan 2023 | |
| NCT05075603 | Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | P1 | completed | 17 | NeoImmuneTech | Jul 2021 | |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery | P1 | terminated | 4 | Hyunseok Kang, MD | Mar 2021 | |
| NCT04984811 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | P2 | terminated | 33 | NeoImmuneTech | Nov 2021 | |
| NCT04893018 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | P1 | terminated | 8 | Fred Hutchinson Cancer Center | May 2022 |
Efineptakin alfa clinical trials: frequently asked questions
- How many Efineptakin alfa clinical trials are there?
- 5 Efineptakin alfa clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is marked completed.
- Are Efineptakin alfa clinical trials recruiting in 2026?
- No active Efineptakin alfa trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Efineptakin alfa being studied for?
- Efineptakin alfa is being studied for AIDS-Related Kaposi Sarcoma, Carcinoma, Non-Small-Cell Lung, High Grade Astrocytic Tumor, HIV Infection, Kaposi Sarcoma and 17 more. The trials are grouped by indication on this page.
- What phase is Efineptakin alfa in?
- Efineptakin alfa clinical trials span 2 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Efineptakin alfa clinical trials?
- The lead sponsor across the most Efineptakin alfa trials is NeoImmuneTech, with 3 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Efineptakin alfaas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: